DE112011102639T5 - Pharmazeutische Zusammensetzung und Verfahren zur Hemmung der Erzeugung oder zur Verstärkung der Eliminierung von P24-Protein - Google Patents

Pharmazeutische Zusammensetzung und Verfahren zur Hemmung der Erzeugung oder zur Verstärkung der Eliminierung von P24-Protein Download PDF

Info

Publication number
DE112011102639T5
DE112011102639T5 DE112011102639T DE112011102639T DE112011102639T5 DE 112011102639 T5 DE112011102639 T5 DE 112011102639T5 DE 112011102639 T DE112011102639 T DE 112011102639T DE 112011102639 T DE112011102639 T DE 112011102639T DE 112011102639 T5 DE112011102639 T5 DE 112011102639T5
Authority
DE
Germany
Prior art keywords
antibody
receptor
activated potentiated
seq
homeopathic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE112011102639T
Other languages
German (de)
English (en)
Inventor
Sergey Alexandrovich Tarasov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE112011102639T5 publication Critical patent/DE112011102639T5/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE112011102639T 2010-08-06 2011-07-15 Pharmazeutische Zusammensetzung und Verfahren zur Hemmung der Erzeugung oder zur Verstärkung der Eliminierung von P24-Protein Withdrawn DE112011102639T5 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2010133046 2010-08-06
RU2010133046/15A RU2517084C2 (ru) 2010-08-06 2010-08-06 Способ и средство для ингибирования продукции или усиления элиминации белка р24
PCT/IB2011/002355 WO2012017322A2 (en) 2010-08-06 2011-07-15 Pharmaceutical composition and method of inhibiting of production or amplifying elimination of p24 protein

Publications (1)

Publication Number Publication Date
DE112011102639T5 true DE112011102639T5 (de) 2013-10-02

Family

ID=44899160

Family Applications (1)

Application Number Title Priority Date Filing Date
DE112011102639T Withdrawn DE112011102639T5 (de) 2010-08-06 2011-07-15 Pharmazeutische Zusammensetzung und Verfahren zur Hemmung der Erzeugung oder zur Verstärkung der Eliminierung von P24-Protein

Country Status (16)

Country Link
US (2) US20120263726A1 (https=)
JP (1) JP2013535483A (https=)
CN (1) CN103179987A (https=)
AU (1) AU2011287286A1 (https=)
CA (1) CA2807523A1 (https=)
DE (1) DE112011102639T5 (https=)
EA (1) EA029791B1 (https=)
ES (1) ES2415029R1 (https=)
GB (1) GB2496356A (https=)
IT (1) ITTO20110636A1 (https=)
MX (1) MX2013001450A (https=)
PH (1) PH12013500233A1 (https=)
RU (1) RU2517084C2 (https=)
SG (1) SG187735A1 (https=)
UA (1) UA112752C2 (https=)
WO (1) WO2012017322A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
EA029436B1 (ru) 2010-07-15 2018-03-30 Олег Ильич ЭПШТЕЙН Комбинированная фармацевтическая композиция для лечения рассеянного склероза и инфекционных заболеваний, сопровождающихся нейротоксическими нарушениями, и способы лечения указанных заболеваний
FR2962656A1 (fr) 2010-07-15 2012-01-20 Oleg Iliich Epshtein Procede pour augmenter l'effet d'une forme activee-potentialisee d'un anticorps
EP2596019A2 (en) 2010-07-21 2013-05-29 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2603623C2 (ru) * 2014-06-06 2016-11-27 Олег Ильич Эпштейн Ветеринарная композиция и способ улучшения жизнеспособности животных, стимуляции прироста живой массы млекопитающих и птиц, повышения эффективности иммунизации, профилактики и/или лечения инфекционных заболеваний (варианты)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
WO2001043779A2 (en) 1999-12-16 2001-06-21 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US7229648B2 (en) 2003-03-14 2007-06-12 Dreyer Lee R Homeopathic formulations useful for treating pain and/or inflammation
US7572441B2 (en) 2002-08-02 2009-08-11 Oleg Iliich Epshtein Media and method for treating pathological syndrome
US7582294B2 (en) 2002-08-02 2009-09-01 Oleg Oliich Epshtein Medicament for treating prostate diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4236069A1 (de) * 1992-10-26 1994-04-28 Werner Dr Bergmann Arzneimittel, insbesondere für orale Einnahme
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
CN1327896C (zh) * 1996-10-10 2007-07-25 探针国际公司 治疗病毒感染的组合物及方法
WO2001016182A2 (en) * 1999-08-27 2001-03-08 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services POLYPEPTIDES THAT BIND HIV gp120 AND RELATED NUCLEIC ACIDS, ANTIBODIES, COMPOSITIONS, AND METHODS OF USE
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2001134982A (ru) * 2001-12-26 2004-02-20 Олег Ильич Эпштейн Способ коррекции иммунного ответа и лекарственное средство
CN1620307A (zh) * 2002-06-28 2005-05-25 扶桑药品工业株式会社 抗hiv剂
EP1543166A4 (en) * 2002-09-27 2009-10-28 Genentech Inc SYNERGETIC COMPOSITIONS FOR PREVENTING AND TREATING THE ACQUIRED IMMUNE WEAKNESS SYNDROME
RU2393873C2 (ru) * 2005-05-02 2010-07-10 Майметикс Корпорейшн Антитело или его фрагмент, имеющие нейтрализующую активность в отношении вич, но не в отношении il2
RU2315058C1 (ru) * 2006-09-27 2008-01-20 Институт органической химии Уфимского научного центра РАН Гликопептид глицирризиновой кислоты с глицил-l-фенилаланином, проявляющий анти-вич-1 активность
US20120263725A1 (en) * 2010-08-06 2012-10-18 Epshtein Oleg Iiiich Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
WO2001043779A2 (en) 1999-12-16 2001-06-21 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US7572441B2 (en) 2002-08-02 2009-08-11 Oleg Iliich Epshtein Media and method for treating pathological syndrome
US7582294B2 (en) 2002-08-02 2009-09-01 Oleg Oliich Epshtein Medicament for treating prostate diseases
US7229648B2 (en) 2003-03-14 2007-06-12 Dreyer Lee R Homeopathic formulations useful for treating pain and/or inflammation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Hum. Antibodies. Monoclonal and recombinant antibodies, 30 years after" von E. Laffly, R. Sodoyer - 2005 - Band 14, - N 1-2, Seiten 33-55
E. Papadopulos-Eleopulos, V. F. Turner, J. M. Papadimitriou, Is a positive western blot proof of HIV infection?, Biotechnology (NY), Juni 1993; 11 (6): 696-707
G. M. Frimel, "Meditsyna", 1987, Seiten 9-33
M. C. Miceli, J. R. Parnes (1993), "Role of CD4 and CD8 in T cell activation and differentiation", Adv. Immunol. 53: 59-122
V. Schwabe "Homeopathic medicines", M., 1967
V. Schwabe "Homeopathic medicines", M., 1967, Seite 14-29

Also Published As

Publication number Publication date
ES2415029R1 (es) 2013-09-17
AU2011287286A1 (en) 2013-03-14
PH12013500233A1 (en) 2017-08-23
GB2496356A (en) 2013-05-08
CA2807523A1 (en) 2012-02-09
RU2010133046A (ru) 2012-02-20
SG187735A1 (en) 2013-03-28
ITTO20110636A1 (it) 2012-02-07
EA201300138A1 (ru) 2014-03-31
MX2013001450A (es) 2013-10-25
WO2012017322A2 (en) 2012-02-09
GB201303865D0 (en) 2013-04-17
ES2415029A2 (es) 2013-07-23
US20130315964A1 (en) 2013-11-28
WO2012017322A3 (en) 2012-04-19
CN103179987A (zh) 2013-06-26
EA029791B1 (ru) 2018-05-31
RU2517084C2 (ru) 2014-05-27
UA112752C2 (uk) 2016-10-25
ES2415029A8 (es) 2013-09-16
US20120263726A1 (en) 2012-10-18
JP2013535483A (ja) 2013-09-12

Similar Documents

Publication Publication Date Title
DE112011102640T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung undPrävention von Infektionskrankheiten
DE112011102639T5 (de) Pharmazeutische Zusammensetzung und Verfahren zur Hemmung der Erzeugung oder zur Verstärkung der Eliminierung von P24-Protein
DE112011102638T5 (de) Pharmazeutische Zusammensetzung und Verfahren zur Behandlung und Prävention der Krankheiten, die durch HIV verursacht werden oder mit HIV zusammenhängen
DE69931377T2 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
DE112011102362T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit neurodegenerativen Erkrankungen in Verbindung stehen
DE112011102649T5 (de) Medikament und Verfahren zur Prävention einer HIV-Kontamination, Prävention und Behandlung von Krankheiten, die durch HIV verursacht werden, und von mit HIV zusammenhängen-den Krankheiten, einschließlich AIDS
DE112011102355T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von funktionellen Erkrankungen oder Zuständen des Gastrointestinaltraktes
DE112011102409T5 (de) Verfahren zur Behandlung der Alzheimer-Krankheit
DE112011102396T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Diabetes und metabolischen Störungen
DE112011102350T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Störungen des Urogenitalsystems
US20120263725A1 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
AT395017B (de) Verfahren zur herstellung eines neuen lymphokins (lk 2) sowie verwendung von lk 2 zur herstellung eines pharmazeutischen praeparates
RU2441023C1 (ru) Лекарственное средство для лечения рассеянного склероза и способ лечения рассеянного склероза
RU2523451C2 (ru) Способ лечения хронической сердечной недостаточности и фармацевтическая композиция для лечения хронической сердечной недостаточности
RU2519196C2 (ru) Лекарственное средство для лечения патологического синдрома и способ лечения рассеянного склероза
RU2525155C2 (ru) Способ лечения хронической сердечной недостаточности и фармацевтическая композиция для комплексной терапии хронической сердечной недостаточности
DE69328605T2 (de) Antikörper enthaltende Arzneimittelzusammensetzung gegen AIDS
DE19944122A1 (de) Histamin-Immunglobulin-Komplexe zur Behandlung von entzündlichen Erkrankungen bei Säugetieren
CA2807529A1 (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
EA032021B1 (ru) Фармацевтическая композиция и способ лечения и профилактики заболеваний, вызванных и/или ассоциированных с вич

Legal Events

Date Code Title Description
R012 Request for examination validly filed

Effective date: 20140513

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee